GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (LTS:0VRQ) » Definitions » Other Long Term Assets

CRISPR Therapeutics AG (LTS:0VRQ) Other Long Term Assets : $27.4 Mil (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is CRISPR Therapeutics AG Other Long Term Assets?

CRISPR Therapeutics AG's other long-term assets for the quarter that ended in Sep. 2024 was $27.4 Mil.

CRISPR Therapeutics AG's quarterly other long-term assets increased from Mar. 2024 ($20.9 Mil) to Jun. 2024 ($26.7 Mil) and increased from Jun. 2024 ($26.7 Mil) to Sep. 2024 ($27.4 Mil).

CRISPR Therapeutics AG's annual other long-term assets declined from Dec. 2021 ($22.2 Mil) to Dec. 2022 ($16.3 Mil) and declined from Dec. 2022 ($16.3 Mil) to Dec. 2023 ($13.6 Mil).

CRISPR Therapeutics AG Other Long Term Assets Historical Data

The historical data trend for CRISPR Therapeutics AG's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Other Long Term Assets Chart

CRISPR Therapeutics AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.14 18.14 22.20 16.27 13.57

CRISPR Therapeutics AG Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.88 13.57 20.88 26.66 27.41

CRISPR Therapeutics AG Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

CRISPR Therapeutics AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (LTS:0VRQ) » Definitions » Other Long Term Assets
Comparable Companies
CYTK NUVL FOLD TRML KRYS BPMC AXSM CORT DNA INSM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
CRSP:USA CRSP:Mexico
Address
Baarerstrasse 14, Zug, CHE, CH-6300
Website
https://www.crisprtx.com
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

CRISPR Therapeutics AG Headlines

No Headlines